Lack of TERT Promoter Mutations in Human B-Cell Non-Hodgkin Lymphoma

被引:9
作者
Lam, Gary [1 ]
Xian, Rena R. [2 ,3 ]
Li, Yingying [1 ]
Burns, Kathleen H. [2 ]
Beemon, Karen L. [1 ]
机构
[1] Johns Hopkins Univ, Dept Biol, Baltimore, MD 21210 USA
[2] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA
[3] Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90095 USA
来源
GENES | 2016年 / 7卷 / 11期
基金
美国国家卫生研究院;
关键词
Telomerase; non-Hodgkin lymphoma; TERT promoter; BLADDER-CANCER; TELOMERASE; TRANSCRIPTION; MELANOMA; SURVIVAL; REGIONS;
D O I
10.3390/genes7110093
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Non-Hodgkin lymphomas (NHL) are a heterogeneous group of immune cell neoplasms that comprise molecularly distinct lymphoma subtypes. Recent work has identified high frequency promoter point mutations in the telomerase reverse transcriptase (TERT) gene of different cancer types, including melanoma, glioma, liver and bladder cancer. TERT promoter mutations appear to correlate with increased TERT expression and telomerase activity in these cancers. In contrast, breast, pancreatic, and prostate cancer rarely demonstrate mutations in this region of the gene. TERT promoter mutation prevalence in NHL has not been thoroughly tested thus far. We screened 105 B-cell lymphoid malignancies encompassing nine NHL subtypes and acute lymphoblastic leukemia, for TERT promoter mutations. Our results suggest that TERT promoter mutations are rare or absent in most NHL. Thus, the classical TERT promoter mutations may not play a major oncogenic role in TERT expression and telomerase activation in NHL.
引用
收藏
页数:6
相关论文
共 30 条
  • [1] Non-Hodgkin Lymphoma: Diagnosis and Treatment
    Ansell, Stephen M.
    [J]. MAYO CLINIC PROCEEDINGS, 2015, 90 (08) : 1152 - 1163
  • [2] Barrans SL, 2003, CLIN CANCER RES, V9, P2133
  • [3] Bell B. J., 2016, MOL CANCER RES, V14, P315, DOI [10.1158/1541-7786.MCR-16-000326941407, DOI 10.1158/1541-7786.MCR-16-000326941407]
  • [4] The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer
    Bell, Robert J. A.
    Rube, H. Tomas
    Kreig, Alex
    Mancini, Andrew
    Fouse, Shaun D.
    Nagarajan, Raman P.
    Choi, Serah
    Hong, Chibo
    He, Daniel
    Pekmezci, Melike
    Wiencke, John K.
    Wrensch, Margaret R.
    Chang, Susan M.
    Walsh, Kyle M.
    Myong, Sua
    Song, Jun S.
    Costello, Joseph F.
    [J]. SCIENCE, 2015, 348 (6238) : 1036 - 1039
  • [5] Update on the molecular biology of mantle cell lymphoma
    Bertoni, F
    Rinaldi, A
    Zucca, E
    Cavalli, F
    [J]. HEMATOLOGICAL ONCOLOGY, 2006, 24 (01) : 22 - 27
  • [6] Insights into the molecular pathogenesis of follicular lymphoma, arising from analysis of geographic variation
    Biagi, JJ
    Seymour, JF
    [J]. BLOOD, 2002, 99 (12) : 4265 - 4275
  • [7] TERT promoter mutations in primary central nervous system lymphoma are associated with spatial distribution in the splenium
    Bruno, Aurelie
    Alentorn, Agusti
    Daniau, Mailys
    Labussiere, Marianne
    Rahimian, Amithys
    Tabouret, Emeline
    Polivka, Marc
    Jouvet, Anne
    Adam, Clovis
    Figarella-Branger, Dominique
    Chretien, Fabrice
    Eimer, Sandrine
    Houillier, Caroline
    Soussain, Carole
    Mokhtari, Karima
    Hoang-Xuan, Khe
    [J]. ACTA NEUROPATHOLOGICA, 2015, 130 (03) : 439 - 440
  • [8] TERT regulates cell survival independent of telomerase enzymatic activity
    Cao, Y
    Li, H
    Deb, S
    Liu, JP
    [J]. ONCOGENE, 2002, 21 (20) : 3130 - 3138
  • [9] Telomeres and telomerase in leukaemia and lymphoma
    Davison, Glenda Mary
    [J]. TRANSFUSION AND APHERESIS SCIENCE, 2007, 37 (01) : 43 - 47
  • [10] Lack of TERT promoter mutations in melanomas with extensive regression
    de Unamuno Bustos, Blanca
    Murria Estal, Rosa
    Perez Simo, Gema
    Oliver Martinez, Vicente
    Llavador Ros, Margarita
    Palanca Suela, Sarai
    Botella Estrada, Rafael
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (03) : 570 - 572